Merit

For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Ipamorelin

Also known as: IPA

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) originally developed by Novo Nordisk and later advanced by Helsinn/Nycomed. It is a selective ghrelin receptor agonist / growth hormone secretagogue (GHRP). Its defining feature versus older GHRPs (GHRP-2, GHRP-6, hexarelin) is that in preclinical and early clinical studies it raised GH without meaningfully increasing ACTH, cortisol, or prolactin. It is not FDA-approved for any indication; a Phase 2 trial for postoperative ileus failed to meet its primary endpoint and clinical development was discontinued. In the wellness/grey market it is sold as a research chemical and used off-label for anti-aging and body-composition goals despite no clinically validated human dose for those uses.

Real-time market data

Pricing for Ipamorelin

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$7.10/mg

range $2.75–$40.49/mg

Sellers

83

from $0.00

45-day trend

+2.1%

vs 45-day avg $/mg

69 of 83 sellers have a current price· 19 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Ipamorelin

237 third-party tests across 34 vendors. Each card links to the full report.

All 237 COAs for Ipamorelin →
Measured purity 98.2%–100.0% across 143 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.42 %
Jun 2026
Janoshik Analytical Limited

For

Ipamorelin

by EZ Peptides· batch EZP-IPA1006032026-15

✓ Vendor-published
99.38 %
Jun 2026
Janoshik Analytical Limited

For

Ipamorelin

by EZ Peptides· batch EZP-IPA1006032026-15

COA on file
Aggregated · 3rd-party listing
99.13 %
Jun 2026
Horizon Analytical

For

Ipamorelin

by Blank Peptides· batch B-9043831-P

✓ Vendor-published
99.98 %
Jun 2026
TrustPointe Analytics Moderate

For

Ipamorelin

by Peptide Partners· batch SPL-4153

COA on file
✓ Vendor-published
99.71 %
Jun 2026
Kovera Labs

For

Ipamorelin

by Peptide Partners· batch IP202606

COA on file
Aggregated · 3rd-party listing
99.90 %
May 2026
ILS Labs Strong

For

IPAMO

by Ion Peptide· batch IP5-05072026

Aggregated · 3rd-party listing
99.90 %
May 2026
ILS Labs Strong

For

IPAMO

by Ion Peptide· batch IP5-05072026

✓ Vendor-published
99.93 %
May 2026
TrustPointe Analytics Moderate

For

Ipamorelin/CJC-1295

by Peptide Partners· batch SPL-3789

COA on file
Aggregated · 3rd-party listing
99.84 %
May 2026
Janoshik Analytical Limited

For

Ipamorelin

by Verified Peptides· batch IPA05261110K

✓ Vendor-published
99.57 %
May 2026
ILS Laboratories

For

Ipamorelin/CJC-1295

by Sunrise Bioresearch· batch CP10MAY26-01

COA on file
Aggregated · 3rd-party listing
99.90 %
May 2026
ILS Labs Strong

For

Ipamorelin

by Ion Peptide· batch IP10-05042026

Aggregated · 3rd-party listing
99.55 %
May 2026
ILS Labs Strong

For

Ipamorelin

by Ion Peptide· batch IP5-05042026

✓ Vendor-published
99.97 %
May 2026
ILS Laboratories

For

Ipamorelin

by Ion Peptide· batch COA-2026-3-LYBQ

COA on file
✓ Vendor-published
99.69 %
May 2026
ILS Laboratories

For

Ipamorelin

by Ion Peptide· batch COA-2026-CBU85Q

COA on file
✓ Vendor-published
99.66 %
May 2026
ILS Laboratories

For

Ipamorelin

by Ion Peptide· batch COA-2026-CBU8SQ

COA on file
Aggregated · 3rd-party listing
99.64 %
May 2026
ILS Labs Strong

For

Ipamorelin

by NG Peptide· batch IPA10-01

Aggregated · 3rd-party listing
99.80 %
May 2026
Vanguard Laboratory Strong

For

Ipamorelin

by Moglabs· batch IPA002

Aggregated · 3rd-party listing
99.28 %
May 2026
Horizon Analytical

For

Ipamorelin

by Pepsgpt· batch P-3437208-P

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical Limited

For

Ipamorelin

by Optima Supply· batch OS-2026-7326

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical Limited

For

Ipamorelin

by Hydro Research Peptides· batch HR-2026-3915

Aggregated · 3rd-party listing
99.80 %
Apr 2026
Bioviridian Moderate · HPLC

For

Ipamorelin

by Prime Peptides· batch 3162026IPA

Aggregated · 3rd-party listing
99.71 %
Apr 2026
ILS Labs Strong

For

Ipamorelin

by Crush Research· batch CRIPA-10-2604-1

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

Ipamorelin

by OROS Research· batch OR-LPIPA5-426-B4

Aggregated · 3rd-party listing
99.16 %
Apr 2026
Janoshik Analytical Limited

For

Ipamorelin

by EZ Peptides· batch EZP-IPA1003282026-14

Research depth

17 citations indexed for Ipamorelin

All research on Ipamorelin →

Study · 2026

Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions

Growth hormone-releasing peptides (GHRPs) comprise a group of small synthetic peptides that can effectively influence growth hormone secretion both in humans and animals.

review · 2026

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

review · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.

review · 2026

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

Background Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients.

review · 2026

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications

Background Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.